Zenas BioPharma, Inc. Retained Earnings
Zenas BioPharma, Inc. (ZBIO) had Retained Earnings of -$957.57 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$957.57M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$846.12M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$765.13M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$524.69M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$957.57M 10-Q · filed 2026-08-13 |
| 2026-03-31 | -$846.12M 10-Q · filed 2026-05-13 |
| 2025-12-31 | -$765.13M 10-Q · filed 2026-08-13 |
| 2025-09-30 | -$524.69M 10-Q · filed 2025-11-12 |
| 2025-06-30 | -$473.19M 10-Q · filed 2025-08-12 |
| 2025-03-31 | -$420.96M 10-Q · filed 2025-05-15 |
| 2024-12-31 | -$387.39M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$334.79M 10-Q · filed 2024-11-12 |
| 2023-12-31 | -$230.40M 10-K · filed 2025-03-11 |